Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DAWN Day One Biopharmaceuticals	$6.48 +2.7%	$7.08	$6.08 ▼ $16.76	$656.83M	-1.24	1.11 million shs	946,344 shs
HURA TuHURA Biosciences	$3.18 -0.9%	$3.73	$1.80 ▼ $7.93	$138.90M	0.53	241,110 shs	50,315 shs
IMTX Immatics	$5.44 +5.8%	$4.52	$3.30 ▼ $13.77	$661.23M	0.87	645,702 shs	446,357 shs
TRVI Trevi Therapeutics	$6.36 +1.6%	$6.24	$2.30 ▼ $7.39	$635.32M	0.62	1.21 million shs	821,828 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DAWN Day One Biopharmaceuticals	+2.69%	+3.35%	-15.63%	-28.48%	-52.91%
HURA TuHURA Biosciences	-0.93%	+5.65%	-18.88%	+31.95%	+317,999,900.00%
IMTX Immatics	+5.84%	+4.62%	+11.70%	+24.20%	-52.90%
TRVI Trevi Therapeutics	+1.60%	+5.47%	+0.79%	+40.71%	+150.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DAWN Day One Biopharmaceuticals	2.6178 of 5 stars	4.6	0.0	0.0	0.0	2.9	2.5	0.0
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	2.1201 of 5 stars	3.6	2.0	0.0	0.0	2.8	1.7	0.0
TRVI Trevi Therapeutics	3.7425 of 5 stars	4.7	3.0	0.0	0.0	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	371.78% Upside
HURA TuHURA Biosciences	3.25	Buy	$12.67	298.32% Upside
IMTX Immatics	3.20	Buy	$14.67	169.61% Upside
TRVI Trevi Therapeutics	3.30	Buy	$18.63	192.85% Upside

Current Analyst Ratings Breakdown

Latest HURA, DAWN, TRVI, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/3/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/3/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
4/1/2025	IMTX Immatics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/25/2025	DAWN Day One Biopharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$39.00 ➝ $27.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DAWN Day One Biopharmaceuticals	$161.92M	4.06	N/A	N/A	$3.98 per share	1.63
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	($4.11) per share	N/A
IMTX Immatics	$144.15M	4.59	N/A	N/A	$2.88 per share	1.89
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DAWN Day One Biopharmaceuticals	-$188.92M	-$0.71	N/A	N/A	N/A	N/A	-22.40%	-19.79%	7/8/2025 (Estimated)
HURA TuHURA Biosciences	-$8.32M	N/A	0.00	∞	N/A	N/A	N/A	-152.88%	N/A
IMTX Immatics	-$104.98M	-$0.17	N/A	N/A	N/A	-47.94%	-15.90%	-9.38%	8/12/2025 (Estimated)
TRVI Trevi Therapeutics	-$29.07M	-$0.45	N/A	N/A	N/A	N/A	-63.31%	-57.06%	8/14/2025 (Estimated)

Latest HURA, DAWN, TRVI, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/27/2025	Q4 2024	IMTX Immatics	-$0.03	$0.48	+$0.51	$0.48	$16.16 million	$15.67 million
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DAWN Day One Biopharmaceuticals	N/A	14.62	14.55
HURA TuHURA Biosciences	N/A	1.54	1.54
IMTX Immatics	N/A	3.98	3.98
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DAWN Day One Biopharmaceuticals	87.95%
HURA TuHURA Biosciences	0.62%
IMTX Immatics	64.41%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
DAWN Day One Biopharmaceuticals	6.20%
HURA TuHURA Biosciences	0.20%
IMTX Immatics	3.30%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	92.38 million	Optionable
HURA TuHURA Biosciences	N/A	43.68 million	42.20 million	N/A
IMTX Immatics	260	121.55 million	115.42 million	Optionable
TRVI Trevi Therapeutics	20	99.89 million	58.13 million	Optionable

HURA, DAWN, TRVI, and IMTX Headlines

Recent News About These Companies

HC Wainwright Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)

May 30 at 1:21 AM | americanbankingnews.com

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

May 29 at 6:14 PM | msn.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Still a Buy?

May 29 at 11:42 AM | marketbeat.com

HC Wainwright Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI)

May 29 at 8:19 AM | marketbeat.com

Trevi Therapeutics to Participate in Upcoming June Conferences

May 29 at 7:30 AM | prnewswire.com

Northern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 27 at 3:03 AM | marketbeat.com

Woodline Partners LP Buys 2,606,370 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 24, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 23, 2025 | marketbeat.com

Trevi Therapeutics' (TRVI) Buy Rating Reiterated at Needham & Company LLC

May 23, 2025 | americanbankingnews.com

Needham & Company LLC Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

May 22, 2025 | marketbeat.com

VR Adviser LLC Reduces Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 22, 2025 | marketbeat.com

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 20, 2025 | prnewswire.com

Point72 Asset Management L.P. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 20, 2025 | marketbeat.com

Cubist Systematic Strategies LLC Invests $368,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 19, 2025 | marketbeat.com

Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 19, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Increased by MPM Bioimpact LLC

May 16, 2025 | marketbeat.com

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

May 10, 2025 | marketbeat.com

Trevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finanznachrichten.de

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, DAWN, TRVI, and IMTX Company Descriptions

Day One Biopharmaceuticals NASDAQ:DAWN

$6.48 +0.17 (+2.69%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$6.63 +0.15 (+2.38%)

As of 04:05 AM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

TuHURA Biosciences NASDAQ:HURA

$3.18 -0.03 (-0.93%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.01 (+0.47%)

As of 05/29/2025 04:04 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Immatics NASDAQ:IMTX

$5.44 +0.30 (+5.84%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$5.38 -0.06 (-1.10%)

As of 04:30 AM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Trevi Therapeutics NASDAQ:TRVI

$6.36 +0.10 (+1.60%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$6.36 0.00 (-0.08%)

As of 05/29/2025 07:56 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time